Erwinase Study in Patients With Acute Lymphoblastic Leukemia
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to allow doctors to use Erwinia L-Asparaginase
(Erwinase®) as a replacement for patients who are allergic to E.coli L-asparaginase or
Pegylated E.coli L-asparaginase as part of the treatment for acute lymphoblastic leukemia
(ALL) or T or B cell lymphoma.
This trial was part of a multi institutional effort by the drug company to make Erwinase
available for use.